Pembrolizumab Induced Hypothyroidism: A Case Report

Home Page
About
Submit A Journal
Submit A Conference
Submit Paper/Book
- Submit a Preprint
- Submit a Book
Contact

Turkish Journal of Internal Medicine
Volume:4 - Supplement 1 Special Issue
Pembrolizumab Induced Hypothyroidism: A Case Report

Pembrolizumab Induced Hypothyroidism: A Case Report

Authors : Sidelya Ecem YİĞİT, İffet Beril GÖKMEN, Yıldız OKUTURLAR

Pages : 149-151

Doi:10.46310/tjim.1078792

View : 21 | Download : 22

Publication Date : 2022-04-01

Article Type : Other Papers

Abstract :Immune checkpoint inhibitors inhibit the inhibitory mechanism on the immune system, their side effects may be autoimmune diseases that occur due to excessive immune response. Pembrolizumab is an immune checkpoint inhibitor targeting PD-1. The most common clinical presentations of thyroid injury induced by pembrolizumab are destructive thyroiditis and overt hypothyroidism. Herein, we presented a case of pembrolizumab induced hypothyroidism.
Keywords : Pembrolizumab, immune checkpoint inhibitors, lung cancer, hypothyroidism, PD 1, non small cell lung

ORIGINAL ARTICLE URL

VIEW PAPER (PDF)

* There may have been changes in the journal, article,conference, book, preprint etc. informations. Therefore, it would be appropriate to follow the information on the official page of the source. The information here is shared for informational purposes. IAD is not responsible for incorrect or missing information.